Isoginkgetin synergizes with doxorubicin for robust co-delivery to induce autophagic cell death in hepatocellular carcinoma

Wang，Yang1,2; Yi，Yunfei1; Yao，Jie2; Wan，Haoqiang2; Yu，Mian1; Ge，Lanlan2; Zeng，Xiaobin2; Wu，Meiying1; Mei，Lin1,3

2022

10.1016/j.actbio.2022.09.035

Acta Biomaterialia   Impact Factor & Quartile

1742-7061

1878-7568

Doxorubicin (DOX) widely used in hepatocellular carcinoma (HCC) can induce serious side effects and drug resistance. Herein, we aimed to seek a strategy to improve the efficacy and reduce the side effects of DOX in HCC based on an autophagy inducer drug called isoginkgetin (ISO). The design of multifunctional nanocarriers based on hyaluronic acid-conjugated and manganese-doped mesoporous silica nanoparticles (HM) for the co-delivery of antitumor drugs against HCC provided an effective and promising antitumor strategy. Our results showed that HM@ISO@DOX could efficiently inhibit HCC cell proliferation through activating autophagy through AMPKa-ULK1 pathway. Moreover, intravenous injection of HM@ISO@DOX significantly suppressed HCC tumor progression in nude mouse HCC model. Collectively, our findings revealed an anti-HCC mechanism of HM@ISO@DOX through autophagy and provide an effective therapeutic strategy for HCC. Statement of significance: In our study, we constructed a co-delivery system by loading ISO and DOX in the mesoporous channels of manganese-doped mesoporous silica nanoparticles, which could be further conjugated with hyaluronic acid to obtain HM@ISO@DOX. The nanocarriers had been demonstrated to be biodegradable under the acidic and reducing tumor microenvironment, as well as to possess the tumor targeting capability via the conjugated hyaluronic acid. In addition, HM@ISO@DOX enhanced the therapeutic efficacy against human HCC tumor through the combinatorial therapies of chemotherapeutics, Mn-mediated chemodynamic therapeutics and autophagic cell death, which might be achieved through AMPK-ULK1 signaling. This work revealed that such a nanomedicine exhibited superior tumor accumulation and antitumor efficiency against HCC with extremely low systemic toxicity in an autophagy-boosted manner.

Autophagy Co-delivery Doxorubicin Hepatocellular carcinoma Isoginkgetin

SCI

English

Corresponding

Fundamental Research Funds for the Central Universities[2019PT320028];Fundamental Research Funds for the Central Universities[2020-RC320-002];Fundamental Research Funds for the Central Universities[2021-RC310-005];National Natural Science Foundation of China[31922042];National Natural Science Foundation of China[32171313];National Natural Science Foundation of China[81971737];

Engineering ; Materials Science

Engineering, Biomedical ; Materials Science, Biomaterials

WOS:000917245100008

ELSEVIER SCI LTD

2-s2.0-85139288974

Scopus

1.School of Pharmaceutical Sciences (Shenzhen),Shenzhen Campus of Sun Yat-sen University,Shenzhen,518107,China
2.Central Laboratory of Longhua Branch and Department of Infectious Disease,Shenzhen People's Hospital (The Second Clinical Medical College,Jinan University; The First Affiliated Hospital,Southern University of Science and Technology,Shenzhen,518020,China
3.Tianjin Key Laboratory of Biomedical Materials,Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy,Institute of Biomedical Engineering,Chinese Academy of Medical Sciences,Peking Union Medical College,Tianjin,300192,China

Wang，Yang,Yi，Yunfei,Yao，Jie,et al. Isoginkgetin synergizes with doxorubicin for robust co-delivery to induce autophagic cell death in hepatocellular carcinoma[J]. Acta Biomaterialia,2022,153.

Wang，Yang.,Yi，Yunfei.,Yao，Jie.,Wan，Haoqiang.,Yu，Mian.,...&Mei，Lin.(2022).Isoginkgetin synergizes with doxorubicin for robust co-delivery to induce autophagic cell death in hepatocellular carcinoma.Acta Biomaterialia,153.

Wang，Yang,et al."Isoginkgetin synergizes with doxorubicin for robust co-delivery to induce autophagic cell death in hepatocellular carcinoma".Acta Biomaterialia 153(2022).